ImmunityBio, Inc. (NASDAQ:IBRX) – Investment analysts at Piper Sandler issued their Q1 2022 earnings estimates for ImmunityBio in a research report issued to clients and investors on Wednesday, April 7th. Piper Sandler analyst J. Catanzaro expects that the company will post earnings per share of ($0.13) for the quarter. Piper Sandler currently has a “Overweight” rating and a $25.00 price target on the stock. Piper Sandler also issued estimates for ImmunityBio’s Q2 2022 earnings at ($0.14) EPS, Q3 2022 earnings at ($0.15) EPS, Q4 2022 earnings at ($0.15) EPS and FY2025 earnings at $0.71 EPS.
Shares of ImmunityBio stock opened at $18.74 on Thursday. ImmunityBio has a 1-year low of $2.83 and a 1-year high of $45.42.
ImmunityBio, Inc, an immunotherapy company, develops a memory T-cell cancer vaccine to combat multiple tumor types without the use of high-dose chemotherapy. It develops an albumin-linked chemotherapeutic therapy (Aldoxorubicin), a novel IL-15 cytokine superagonist (N-803), checkpoint inhibitors, macrophage polarizing peptides, bi-specific fusion proteins targeting TGFb and IL-12, adenovirus, and yeast vaccine therapies targeting tumor-associated antigens and neoepitopes.
See Also: Treasury Bonds
Receive News & Ratings for ImmunityBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunityBio and related companies with MarketBeat.com's FREE daily email newsletter.